Physician
Silverpath, INC.
Silverpath, INC. was paid $1.03M by Medicaid between Aug 2020 and Dec 2024, across 44 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 52% of everything it billed.
33Billing provider infoSILVERPATH, INC.
BLUE BELL, PA 19422
BLUE BELL, PA 19422
33aNPI1750944526assigned 04/17/2019
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$1.03M
24GClaims130,302
24DCodes billed44
24AFirst – last monthAug 2020 – Dec 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Pennsylvania
Rank by total paid#6 of 163
Median peer was paid$15K
This provider vs. median67×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 24,455 | $121K | |
| 2021 | 36,575 | $336K | |
| 2022 | 23,124 | $38K | |
| 2023 | 22,778 | $151K | |
| 2024incomplete | 23,370 | $378K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 52% | 19,768 | 11,467 | $535K |
| 87481 | 11% | 10,419 | 8,556 | $113K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.0% | 4,584 | 2,327 | $41K |
| 87631 | 3.9% | 2,637 | 2,203 | $40K | |
| 87653 | 3.8% | 12,673 | 10,343 | $39K | |
| 87641 | 3.1% | 10,349 | 8,502 | $32K | |
| 87500 | 3.0% | 10,063 | 8,446 | $31K | |
| 87529 | 2.6% | 3,742 | 3,139 | $27K | |
| 87640 | 1.7% | 7,919 | 6,453 | $17K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.6% | 3,676 | 3,107 | $16K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.3% | 4,773 | 3,930 | $14K |
| 87625 | 1.3% | 3,267 | 2,725 | $13K |
32 more codes
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.1% | 2,586 | $12K |
| 87511 | <1% | 3,286 | $9K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,222 | $9K |
| 87486 | <1% | 3,131 | $9K | |
| 87541 | <1% | 3,087 | $8K | |
| 87581 | <1% | 3,088 | $8K | |
| 87561 | <1% | 2,448 | $7K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,550 | $7K |
| 87563 | <1% | 2,387 | $6K | |
| 81514 | <1% | 34 | $5K | |
| 87556 | <1% | 1,470 | $4K | |
| 87493 | <1% | 1,393 | $4K | |
| 81226 | <1% | 718 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 505 | $3K |
| 81225 | <1% | 699 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 569 | $2K |
| 81231 | <1% | 625 | $2K | |
| 81230 | <1% | 399 | $1K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 542 | $1K |
| 81479 | Unlisted molecular pathology procedure | <1% | 786 | $974.23 |
| 81227 | <1% | 631 | $820.50 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 703 | $685.64 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 184 | $436.86 |
| 81291 | <1% | 385 | $427.23 | |
| 81328 | <1% | 228 | $400.67 | |
| 81241 | <1% | 136 | $226.21 | |
| 87471 | <1% | 192 | $205.69 | |
| 81240 | <1% | 136 | $193.59 | |
| 81401 | <1% | 102 | $109.93 | |
| 81355 | <1% | 128 | $70.77 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 64 | $66.87 |
| 87505 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRELSON, SHEA (CEO/CO-OWNER)
| Provider | Location | Paid |
|---|---|---|
| Vikor Scientific, LLC | Charleston, SC | $27.03M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.